Lates News

On May 14th, Novo Nordisk announced that it has reached a partnership and licensing agreement with the American biotechnology company Septerna to jointly develop oral small molecule drugs for the treatment of obesity, type 2 diabetes, and other cardiovascular metabolic diseases. The agreement is expected to be worth up to 2.2 billion dollars.